A5102715542- Inflammasome and immune disorders
- Respiratory viral infections research
- Mast cells and histamine
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- SARS-CoV-2 and COVID-19 Research
- Immune cells in cancer
- interferon and immune responses
- Pneumonia and Respiratory Infections
- Extracellular vesicles in disease
- COVID-19 Clinical Research Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunotherapy and Immune Responses
- NF-κB Signaling Pathways
- Vaccine Coverage and Hesitancy
- Delphi Technique in Research
- Immune responses and vaccinations
- Virus-based gene therapy research
- Respiratory Support and Mechanisms
- Viral Infections and Vectors
- Viral Infections and Immunology Research
- Cytomegalovirus and herpesvirus research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- IL-33, ST2, and ILC Pathways
University of Technology Sydney
2022-2024
Centenary Institute
2022-2023
Patients with chronic obstructive pulmonary disease (COPD) develop more severe coronavirus (COVID-19); however, it is unclear whether they are susceptible to acute respiratory syndrome 2 (SARS-CoV-2) infection and what mechanisms responsible for disease.
Excessive inflammation-associated coagulation is a feature of infectious diseases, occurring in such conditions as bacterial sepsis and COVID-19. It can lead to disseminated intravascular coagulation, one the leading causes mortality worldwide. Recently, type I interferon (IFN) signaling has been shown be required for tissue factor (TF; gene name F3) release from macrophages, critical initiator providing an important mechanistic link between innate immunity coagulation. The mechanism...
Abstract Current vaccines against SARS-CoV-2 substantially reduce mortality, but protection infection is less effective. Enhancing immunity in the respiratory tract, via mucosal vaccination, may provide and minimise viral spread. Here, we report testing of a subunit vaccine mice, consisting Spike protein with TLR2-stimulating adjuvant (Pam 2 Cys), delivered to mice parenterally or mucosally. Both routes vaccination induce substantial neutralising antibody (nAb) titres, however, uniquely...
TANK-binding kinase 1 (TBK1) is a key signalling component in the production of type-I interferons, which have essential antiviral activities, including against SARS-CoV-2. TBK1, and its homologue IκB kinase-ε (IKKε), can also induce pro-inflammatory responses that contribute to pathogen clearance. While initially protective, sustained engagement interferons associated with damaging hyper-inflammation found severe COVID-19 patients. The contribution TBK1/IKKε these unknown. Here we find...
Multiple SARS-CoV-2 vaccine candidates have been approved for use and had a major impact on the COVID-19 pandemic. There remains, however, significant need vaccines that are safe, easily transportable protective against infection, as well disease. Mucosal vaccination is favored its ability to induce immune memory at site of making it appealing strategies. In this study we performed in-depth analysis responses in mice subunit recombinant spike protein formulated with delta-inulin adjuvant...
Abstract Next-generation vaccines are required to address the evolving nature of SARS-CoV-2 and protect against emerging pandemic threats from other coronaviruses. These should aim elicit broad-protection, provide long-lasting immunity facilitate equitable access for all populations. In this study, a panel chimeric, full-length spike antigens were developed that incorporate mutations previous, circulating predicted variants. The lead candidate (CoVEXS5) was obtained high-yield production...
Abstract TANK-binding kinase 1 (TBK1) is a key signalling component that drives the production of type-I interferons (IFNs), which have essential antiviral activities including against SARS-CoV-2. TBK1 and its homolog IκB kinase-ε (IKKε) can also induce pro-inflammatory factors contribute to pathogen clearance. While initially protective, delayed engagement IFN associated with lethal hyper-inflammation seen in severe COVID-19 patients. The contribution TBK1/IKKε this response unknown. We...
<b>Background:</b> Chronic respiratory disease is a well-characterised risk factor for increased hospitalisation and mortality in COVID-19 patients. There conflicting evidence as to whether asthma patients are predisposed SARS-CoV-2 infection or more severe outcomes. These clinical studies often confounded by severity inhaled corticosteroids management. <b>Aims objectives:</b> To determine at of greater inflammatory responses following infection. We hypothesise that support viral replication...
Abstract Current vaccines against SARS-CoV-2 substantially reduce mortality, but protection infection is less effective. Enhancing immunity in the respiratory tract, via mucosal vaccination, may provide and minimise viral spread. We tested a novel subunit vaccine mice, consisting of Spike protein with TLR2-stimulating adjuvant, delivered to mice parenterally or mucosally. Both routes vaccination induced substantial neutralising antibody (nAb) titres, however, uniquely generated anti-Spike...